{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:48:23Z","timestamp":1762098503865,"version":"3.44.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006221","name":"Cordis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL007604"],"award-info":[{"award-number":["T32 HL007604"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K23HL118138"],"award-info":[{"award-number":["1K23HL118138"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ahj.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T03:17:41Z","timestamp":1415589461000},"page":"222-233.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-1763","authenticated-orcid":false,"given":"Pallav","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Z.","family":"Galper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.11.002_bb0005","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0015","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_bb0020","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1161\/01.CIR.103.15.1967","article-title":"Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials","volume":"103","author":"Cutlip","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0025","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0030","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_bb0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0040","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0045","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_bb0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience\/Promus versus Cypher to reduce late loss after stenting (Excellent) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0055","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the Reset trial (real safety and efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0060","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0065","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0070","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0075","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.0000140721.27004.4B","article-title":"Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials","volume":"110","author":"Cutlip","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0272989X8300300403","article-title":"The markov process in medical prognosis","volume":"3","author":"Beck","year":"1983","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ahj.2014.11.002_bb0085","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2008.01.042","article-title":"Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model","volume":"51","author":"Garg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0090","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2012.08.966","article-title":"A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the cathpci registry of the National Cardiovascular Data Registry, 2010 through june 2011","volume":"60","author":"Dehmer","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0735-1097(02)02862-0","article-title":"Long-term follow-up of coronary artery disease presenting in young adults","volume":"41","author":"Cole","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.amjcard.2003.07.022","article-title":"Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non\u2013ST-elevation myocardial infarction","volume":"92","author":"Lloyd-Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0120","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcin.2012.05.010","article-title":"Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients","volume":"5","author":"Rao","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_bb0125","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2011.07.021","article-title":"Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the Horizons-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial","volume":"58","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_bb0130","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/CIRCULATIONAHA.107.694273","article-title":"Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?","volume":"116","author":"Spencer","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0135","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","volume":"123","author":"Hochholzer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0140","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0145","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1161\/hc5001.100794","article-title":"Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (Stent-Pami) trial","volume":"104","author":"Cohen","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0150","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","article-title":"Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk","volume":"117","author":"Greving","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0155","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0160","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1525-1497.1998.00246.x","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"13","author":"Augustovski","year":"1998","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0165","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","article-title":"The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life","volume":"156","author":"Gage","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2014.11.002_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_bb0175","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-Cure study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_bb0180","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_bb0185","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_bb0190","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial","volume":"380","author":"Camenzind","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_bb0195","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jcin.2013.05.005","volume":"6","author":"Dangas","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_bb0200","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.STR.24.6.796","article-title":"Long-term survival after first-ever stroke: The Oxfordshire Community Stroke project","volume":"24","author":"Dennis","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2014.11.002_fr0005","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.amjcard.2009.06.059","article-title":"Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction","volume":"104","author":"Lee","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcin.2010.10.007","article-title":"Four-year follow-up of TYPHOON (trial to assess the use of the cypher sirolimus-eluting coronary stent in acute myocardial infarction treated with balloon angioplasty)","volume":"4","author":"Spaulding","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jacc.2007.04.029","article-title":"Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb\/IIIa inhibitor infusion in patients with myocardial infarction: results from the strategy study","volume":"50","author":"Valgimigli","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4244\/EIJV7I9A164","article-title":"Five-year clinical follow-up from the MISSION! Intervention study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial","volume":"7","author":"Boden","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2014.11.002_fr0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1540-8183.2007.00270.x","article-title":"Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (selection)","volume":"20","author":"Chechi","year":"2007","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0030","doi-asserted-by":"crossref","first-page":"164.e161","DOI":"10.1016\/j.ahj.2007.04.007","article-title":"Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty","volume":"154","author":"Diaz de la Llera","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0035","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4244\/EIJV7I12A217","article-title":"Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the compare prospective randomised controlled trial","volume":"7","author":"Kedhi","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2014.11.002_fr0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcin.2010.11.003","volume":"4","author":"Vink","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0045","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2009.09.046","article-title":"Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial","volume":"55","author":"Violini","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0050","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4244\/EIJV7I8A148","volume":"7","author":"Kang","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2014.11.002_fr0055","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRTION-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0060","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jcin.2008.01.006","article-title":"Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction","volume":"1","author":"Hannan","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2012.01.073","article-title":"Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (xiencev stent vs. Cypher stent in primary PCI for acute myocardial infarction) trial","volume":"60","author":"Hofma","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCINTERVENTIONS.108.794578","article-title":"Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction","volume":"1","author":"Jensen","year":"2008","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.amjcard.2009.03.015","article-title":"Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction","volume":"104","author":"Juwana","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijcard.2009.09.466","article-title":"Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial","volume":"147","author":"Kim","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ahj.2009.04.025","article-title":"Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina\u2014comparison of the effects of drug-eluting versus bare-metal stents","volume":"158","author":"Leibundgut","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0095","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMoa0801485","article-title":"Drug-eluting or bare-metal stents for acute myocardial infarction","volume":"359","author":"Mauri","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0100","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","article-title":"Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial","volume":"380","author":"Sabate","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0105","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0110","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehm402","article-title":"Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction","volume":"28","author":"Kastrati","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0115","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ahj.2009.03.016","article-title":"Benefits of drug-eluting stents as compared with bare metal stent in ST-segment elevation myocardial infarction: four year results of the paclitaxel or sirolimus-eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial","volume":"158","author":"Di Lorenzo","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0125","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","article-title":"Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial","volume":"298","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_fr0130","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0135","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacc.2009.11.026","volume":"55","author":"Damman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(05)67222-4","article-title":"5-year outcome of an interventional strategy in non\u2013ST-elevation acute coronary syndrome: The British Heart Foundation RITA 3 randomised trial","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjcard.2010.12.043","article-title":"Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non\u2013ST-segment elevation myocardial infarction","volume":"107","author":"Hannan","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0150","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(06)69416-6","article-title":"5-year outcomes in the FRISC-2 randomised trial of an invasive versus a non-invasive strategy in non\u2013ST-elevation acute coronary syndrome: a follow-up study","volume":"368","author":"Lagerqvist","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0155","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1056\/NEJMoa0807986","article-title":"Early versus delayed invasive intervention in acute coronary syndromes","volume":"360","author":"Mehta","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0160","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjcard.2011.05.020","article-title":"Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies","volume":"108","author":"Wiviott","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2011.07.106","article-title":"Three-year follow-up of the multicentre evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study (MULTISTRATEGY)","volume":"165","author":"Valgimigli","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0170","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcin.2012.05.010","article-title":"Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients","volume":"5","author":"Rao","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0175","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.111.046599","article-title":"Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the J-Cypher registry","volume":"125","author":"Kimura","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0180","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0185","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1161\/CIRCULATIONAHA.104.532242","article-title":"Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the E-Cypher registry","volume":"113","author":"Urban","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience\/Promus versus Cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.112.104059","article-title":"Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial (RESET)","volume":"126","author":"Kimura","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcin.2010.11.006","article-title":"The SPIRIT V study: a clinical evaluation of the Xience V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions","volume":"4","author":"Grube","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0205","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jacc.2008.01.020","article-title":"A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (cobalt chromium stent with antiproliferative for restenosis) II study","volume":"51","author":"Krucoff","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0210","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jcin.2010.07.008","volume":"3","author":"Leon","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0215","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.111.026732","volume":"124","author":"Massberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","article-title":"Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial","volume":"62","author":"Natsuaki","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0225","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2010.03.086","volume":"56","author":"Park","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0230","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","volume":"57","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0235","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/eurheartj\/ehp352","article-title":"Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the intracoronary stenting and angiographic results: test efficacy of 3 limus-eluting stents (ISAR-TEST-4) trial","volume":"30","author":"Byrne","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0240","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2010.03.020","article-title":"2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents","volume":"55","author":"Byrne","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0245","doi-asserted-by":"crossref","first-page":"45M","DOI":"10.1016\/j.amjcard.2007.08.021","article-title":"Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients","volume":"100","author":"Gershlick","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0250","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0255","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.295.8.895","article-title":"Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial","volume":"295","author":"Morice","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_fr0260","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.108.803528","volume":"119","author":"Stone","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0265","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.03.005","article-title":"Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial","volume":"57","author":"Yeung","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0270","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/eurheartj\/ehm424","article-title":"Taxus VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-luting with bare metal stents for treatment of long, complex lesions","volume":"28","author":"Grube","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.11.002_fr0275","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.110.015453","article-title":"Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-diabetes): results from the ESSENCE-diabetes trial","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0280","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jcin.2011.05.024","article-title":"Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (percutaneous treatment of long native coronary lesions with drug-eluting stent-III) trial","volume":"4","author":"Park","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0285","first-page":"286","article-title":"A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial","volume":"2","author":"Serruys","year":"2006","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2014.11.002_fr0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcin.2008.12.011","article-title":"The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus\/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries) trial","volume":"2","author":"Verheye","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.11.002_fr0295","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0300","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.107.750109","article-title":"Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease","volume":"117","author":"Park","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0305","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0310","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_fr0315","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.11.002_fr0320","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.11.002_fr0325","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.11.002_fr0330","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: Aa randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0335","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.11.002_fr0340","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.11.002_fr0345","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314006619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314006619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:53:10Z","timestamp":1757569990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314006619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0002870314006619"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.11.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}